Tech Digest

History’s Biggest Breakthrough in Anti-Aging Medicine

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

July 5, 2016

Dear Reader,

Michael West, known as the father of regenerative medicine, gave a talk last week that historians will remember as the world’s first look at the biotechnology that changed everything forever. At the annual meeting of Mensa, he reported on the progress of regenerative medicine—from the stem cell breakthroughs that he pioneered to his current research.

West’s presentation—despite his calm understated manner—is frankly staggering. It is a roadmap to the development of a biotechnology that can cure the worst diseases and traumas. It can even reverse human aging.

Hacking into Hayflick limit

Let’s start this discussion with the title of his presentation, "Hayflick Rewound, Implications of Reversing the Aging of Human Cells." The phrase “Hayflick Rewound” refers to the Hayflick limit, which is the number of times cells can reproduce themselves.

Leonard Hayflick demonstrated in 1961 that adult cells lose telomeres, the gene sequence that holds the two halves of your DNA’s double helix together when cells divide to replicate (mitosis). As the telomere sequence is shortened, the two DNA helices can no longer rejoin correctly for replication, so it begins to malfunction and then dies.

Before the discovery of telomeres, many leading biologists believed that exterior factors caused cell aging and death. Hayflick showed that the biological clock is ticking away inside each of our cells.

Our bodies, however, have some cells that don’t age. They are known as immortal cells. These are the cells of your germline, including the sperm and ovum. Germ cells remain young even in very old people because their telomeres are constantly replenished.

Embryonic cells also share this immortal characteristic. Unlike adult cells, embryonic cells can replicate under the right conditions forever. At about the eighth week, however, embryonic cells become adult cells and the clock of aging begins to tick.

Every cell replication from that point on shortens the telomere thread of life.

Restoring immortality in adult cells

Some scientists began to question if imparting germline immortality to adult cells was possible. Initially, the scientific community rejected the possibility almost completely. Research centered instead on harnessing embryonic stem cells for therapeutic purposes.

Yet, a few scientists continued their work on restoring embryonic immortality and powers to adult cells, which is called pluripotency. You may have heard of Shinya Yamanaka, the Japanese scientist who won a Nobel prize in 2012 for finding, through exhaustive trial and error, four genes that can restore pluripotency to adult cells.

Few people know, however, that Michael West had already realized the power of those genes and applied for a patent on their use. West founded the pioneering stem cell company Geron and reacquired its regenerative medicine patents for his current company, BioTime. (*see disclosure below)

Today, West—and other scientists—routinely revert adult cells into pluripotent cells via genetic engineering in vitro (test tubes, petri dishes, and so on). He’s even done so with skin cells taken from el jefe John Mauldin’s left arm as well as my own.

In the dish, my fibroblasts were converted to cells with the remarkable characteristics of embryonic stem cells. These are called induced pluripotent stem (iPS) cells and they make embryonic stem cells obsolete. Regulators, however, haven’t allowed this shift yet. My iPS cells were then engineered to become heart muscle cells, identical to those beating in my chest now… except that they are young and completely vigorous.

Regenerative powers of embryonic cells

Youth is not the only critical attribute of embryonic or iPS cells.

You’ve undoubtedly seen pictures of embryos or developing fetuses. Both are recognizably human, with fingers and noses and all the other characteristics that make us homo sapiens. Most people don’t know, however, that there is a point when the embryo makes a sudden shift from embryonic to fetal status.

That happens about eight weeks after fertilization. It’s not visible. On the surface, the embryo looks exactly the same as the fetus, but the change is profound.

If some sort of injury occurs early enough in the embryonic state, complete regeneration can take place. If, for example, the embryo’s arm is severed, another one will grow.

Once the embryo has all its parts in place (including nervous system, organs, and limbs), it turns into a fetus. From then on, cells scar rather than regenerate.

Reverting embryonic status in vivo

Enormous genetic changes take place on the cellular level as the embryo becomes a fetus. This transition is critically important for scientists who want to use embryonic or iPS cells for medical therapies.

Many scientists working with stem cells don’t actually know what kind of cells they are using. Embryonic and fetal cells look exactly alike, but a cell that has just become fetal is completely changed on the genetic level—losing many of its medical properties.

West and his team, therefore, have been collecting and analyzing genetic data about this transition using thousands of cell sources, including John Mauldin’s and mine. Nobody else has seriously studied this transition or acquired a fraction of the information that BioTime has developed. And nobody knows more about this transformation than West.

This is where the story gets really, really interesting. West’s daughter once asked him for help with a school project about the Mexican salamander, a species that retains embryonic tissue regeneration capabilities throughout their lives.

Other lizards can regrow tails, but the Mexican salamander (Ambystoma mexicanum) can regrow limbs and damaged organs. By the way, these animals can be changed to adult—with the help of hormones. They then transform into an animal that bears little resemblance to the salamander found in nature.

Helping his daughter out with the school project, West realized that adult cells might be also shifted back to embryonic status in vivo (in living organisms) just as they are in vitro. While iPS cells have huge therapeutic potential, the restoration of embryonic regenerative abilities (induced tissue regeneration or iTR) in the cells of living people is world changing.

It would enable the sort of healing seen only in science fiction stories and video games. It would restore youthful health to old cells and extend the Hayflick limit. Medicine, aging, and life spans as we know them today would change in nearly unimaginable ways.

There’s a lot more to this story. Next week, I’ll tell you how some of the world’s top experts in artificial intelligence are working with West to solve the genomic puzzles associated with iTR. I’ll also tell you why I think the arrival of this revolutionary biotechnology is inevitable. And it will be sooner than you think.

In the meantime, here’s the link to the BioTime iTR video.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics


Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest

Your privacy is very important to us. Please review our Privacy Policy.


« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This

We welcome your comments. Please comply with our Community Rules.


There are no comments at this time.

Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact


The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics